Ignite Creation Date:
2025-12-25 @ 12:20 AM
Ignite Modification Date:
2025-12-25 @ 10:24 PM
Study NCT ID:
NCT02297958
Status:
COMPLETED
Last Update Posted:
2020-08-31
First Post:
2014-11-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Sponsor:
Rennes University Hospital
Organization:
Study Overview
Official Title:
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IFFaLCCO
Brief Summary:
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: